Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasm Metastasis 5Colorectal Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Rectal Neoplasms 2Neoplasms 2Lymphoma 2Insulin-Like Growth Factor I, Resistance To 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoid Tumor 2Sarcoma, Ewing 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Jaundice 1Immunoblastic Lymphadenopathy 1

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × ganitumab × Clear all
NCT01024387 2018-03-08

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 7 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡